Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

NCT00441883 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

176

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Open Angle Glaucoma
Ocular Hypertension
Pigmentary Glaucoma
Pseudoexfoliative Glaucoma

Interventions

DRUG: PF-03187207 and Latanoprost Vehicle
DRUG: Latanoprost 0.005% and PF-03187207 Vehicle

Sponsor

Bausch & Lomb Incorporated

Collaborators

[object Object]